Related Experiment Video
Updated: Jun 19, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy
Zubaria Farzeen1, Rana Rashad Mahmood Khan1, Ayoub Rashid Chaudhry1
1Department of Chemistry, Government College University Lahore, Lahore, Punjab, Pakistan.
Objective:
Dostarlimab, a humanized monoclonal PD-1 blocking antibody, is being tested as a cancer therapy in this review. Specifically, it addresses mismatch repair failure in endometrial cancer and locally progressed rectal cancer patients.
Data Sources:
A thorough database search found Dostarlimab clinical trials and studies. Published publications and ongoing clinical trials on Dostarlimab's efficacy as a single therapy and in conjunction with other medicines across cancer types were searched.
Data Summary:
The review recommends Dostarlimab for endometrial cancer mismatch repair failure, as supported by GARNET studies. The analysis also highlights locally advanced rectal cancer findings. In the evolving area of cancer therapy, immune checkpoint inhibitors including pembrolizumab, avelumab, atezolizumab, nivolumab, and durvalumab were discussed.
Conclusions:
Locally advanced rectal cancer patients responded 100% to Dostarlimab. Many clinical trials, including ROSCAN, AMBER, IOLite, CITRINO, JASPER, OPAL, PRIME, PERLA, and others, are investigating Dostarlimab in combination treatment. This research sheds light on Dostarlimab's current and future possibilities, in improving cancer immunotherapy understanding.
Insights
Dostarlimab shows promise in treating endometrial cancer with mismatch repair failure and rectal cancer. This PD-1 inhibitor is being explored in various clinical trials for advanced cancer immunotherapy.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Dostarlimab is a humanized monoclonal antibody targeting PD-1.
- It is investigated for cancer treatment, particularly in mismatch repair deficient (dMMR) endometrial cancer and locally advanced rectal cancer.
Purpose of the Study:
- To review the efficacy of Dostarlimab as a monotherapy and in combination treatments.
- To assess its role in endometrial and rectal cancers.
Main Methods:
- Comprehensive literature search of Dostarlimab clinical trials and studies.
- Analysis of published data and ongoing trials across various cancer types.
Main Results:
- Dostarlimab is recommended for dMMR endometrial cancer based on GARNET studies.
- 100% response rate observed in locally advanced rectal cancer patients treated with Dostarlimab.
Conclusions:
- Dostarlimab demonstrates significant potential in treating specific cancer types.
- Ongoing trials are evaluating Dostarlimab in combination therapies, expanding its role in cancer immunotherapy.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...